<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175940</url>
  </required_header>
  <id_info>
    <org_study_id>VEGF001</org_study_id>
    <nct_id>NCT02175940</nct_id>
  </id_info>
  <brief_title>VEGF and PEDF in Patients With Myopic Choroidal Neovascularization</brief_title>
  <official_title>Effect of Intravitreal Ranibizumab Injection on Aqueous Humor Concentrations of Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Patients With Myopic Choroidal Neovascularization.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ciro Costagliola</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Francesco Semeraro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roberto dell'Omo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mario R Romano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fabiana Aceto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rodolfo Mastropasqua</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Antonio Porcellini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Università degli Studi di Brescia</source>
  <brief_summary>
    <textblock>
      This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in
      eyes with mCNV treated with IVB.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>vascular endothelial growth factor (VEGF) aqueous levels</measure>
    <time_frame>2 months</time_frame>
    <description>VEGF aqueous levels before and after intravitreal ranibizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pigment epithelium-derived factor (PEDF) aqueous levels</measure>
    <time_frame>2 months</time_frame>
    <description>PEDF aqueous levels before and after intravitreal ranibizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>best-corrected visual acuity</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central retinal thickness</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Myopic Choroidal Neovascularization</condition>
  <condition>VEGF Aqueous Level</condition>
  <condition>PEDF Aqueous Level</condition>
  <arm_group>
    <arm_group_label>Myopic Choroidal Neovascularization patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients undergoing cataract surgery</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with myopic Choroidal Neovascularization treated with intravitreal ranibizumab at
        the Medical Retina Department, University of Molise, Campobasso, Italy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathologic myopia, defined as spherical equivalent &gt;6 diopters and axial length &gt;26 mm

          -  posterior pole myopic retinal changes (posterior staphyloma, chorioretinal atrophy,
             papillary crescent);

          -  fluorescein angiography, indocyanine green angiography and optical coherence
             tomography detection of the subfoveal or juxtafoveal choroidal neovascularization

          -  clear ocular media;

        Exclusion Criteria:

          -  previous treatment for choroidal neovascularization, including the previous
             intravitreal drug injection or PDT

          -  presence of other maculopathy as diabetic retinopathy or retinal vascular occlusion

          -  history of recent myocardial infarction or other thromboembolic events

          -  ongoing uncontrolled hypertension or glaucoma

          -  refractive media opacities

          -  previous eye surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Retina Department, University of Molise</name>
      <address>
        <city>Cambpobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Brescia</investigator_affiliation>
    <investigator_full_name>Andrea Russo</investigator_full_name>
    <investigator_title>MD, PhD Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Pigment epithelium-derived factor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

